BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Space station changes command, setting stage for Crew 11 departure - 2Gym tied to outbreak of obscure disease that spreads through mist
- 3EU states agree first step for Ukraine reparations fund
- 4Flourishing in a Cutthroat Work Market: Vocation Methodologies
- 5Figure out How to Reveal Stowed away Open Record Rewards
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Are IDF reservists properly armed during post-war operations?
- 5 VIPs That Changed Style
- The Best Web-based Courses for Expertise Improvement
- Flu season is just beginning, but doctors are already on high alert
- Home Remodel Administrations: Change Your Residing Space
- Figure out How to Streamline Eco-friendliness in Your Volvo XC40
- How do my eyes adjust to the dark and how long does it take?
- Top 10 Moving Style Architects of the Year
